The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Update on Legislation, Advocacy Efforts to Advance Rheumatology

Update on Legislation, Advocacy Efforts to Advance Rheumatology

September 1, 2014 • By Joseph Flood, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ICD-10 delay was something pundits said could not be done and which the HHS Secretary said would never happen, but we got it done together. Although rheumatologists should continue to prepare for ICD-10, the ACR also has a legislative solution to ease implementation challenges for practices. Our bill received positive feedback on the Hill, and we will be well positioned to move it if necessary.

You Might Also Like
  • ACR Aims to Keep Rheumatology on Congressional Radar in 2014
  • Congress Can Begin Work to Advance Rheumatology Before New Year
  • Rheumatology Advocacy Starts at Home
Explore This Issue
September 2014
Also By This Author
  • ACR’s Benchmark Tool Quantifies Data about Rheumatology Workforce, Clinical Practice

Access to Treatment

As rheumatologists, we are fortunate to have breakthrough treatments that can significantly improve our patients’ lives. Because of cost, access to these treatments is an issue for too many people. H.R. 460, the Patients’ Access to Treatments Act, is our bill to make biologics more affordable by limiting cost sharing in commercial, employer and exchange plans with specialty tiers. These schemes put these medications and the improvements associated with them out of the reach of our patients. This is shameful and unacceptable, and it calls us to action.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Arthritis Foundation (AF) has been our strong partner, along with the Lupus Foundation, National Psoriasis Foundation, Spondylitis Association and 20 other patient and physician groups. The ACR and AF co-founded the Coalition for Accessible Treatments, under which these organizations work together. This effort, along with your letters, calls and meetings, has produced more than 130 bipartisan co-sponsors for H.R. 460, and we have been able to present testimony before Congress to explain the importance of our bill. Next steps are the introduction of a Senate bill and a hearing in the Senate committee. Our advocacy staff will alert you when a Senate bill is introduced so you can urge your Senators to sponsor it.

The facts that the ACR was invited to testify before Congress on access to treatments and was the only healthcare provider society invited to testify were important milestone markers along the inroads we have made together in Congress. You can view the testimony, eloquently presented by GAC Chair William F. Harvey, MD, MSc, on the Energy and Commerce website.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

GAC Chair William F. Harvey, MD, MSc, testified before Congress on the issue of access to treatment in June 2014.
GAC Chair William F. Harvey, MD, MSc, testified before Congress on the issue of access to treatment in June 2014.

Funding for Research

Another potential breakthrough, although it was fleeting, was related to the federal budget. For the first time since 2009, our nation had a budget agreement! We had hoped it would end the string of budget standoffs and continuing resolutions (and the flat research funding that results from those CRs), and that normal appropriations processes would again be followed, but this has not materialized.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Billing/Coding, Biologics & Biosimilars, Drug Updates, Legislation & Advocacy, Practice Management, President's Perspective, Professional Topics, Quality Assurance/Improvement Tagged With: AC&R, Advocacy, American College of Rheumatology, Association of Rheumatology Professionals (ARP), Billing, Biologics, Biosimilars, Coding, drug, ICD-10, Legislation, Medicare, Practice Management, Research, rheumatologist, SGR, TechnologyIssue: September 2014

You Might Also Like:
  • ACR Aims to Keep Rheumatology on Congressional Radar in 2014
  • Congress Can Begin Work to Advance Rheumatology Before New Year
  • Rheumatology Advocacy Starts at Home
  • Much at Stake for Rheumatology in Lame Duck Session of Congress

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)